Authors

Julia R. White, MD

Latest:

Dr. White Discusses Exceptions in the Z11 Trial

Dr. Julia White from Community Memorial Hospital Discusses Exceptions in the Z11 Trial

Julia Rotow, MD

Latest:

Treatment Options for BRAF-Mutated Metastatic NSCLC

Panelists discuss evolving treatment approaches for BRAF-mutated metastatic lung cancer and their clinical impact.

Julia von Tresckow, MD

Latest:

Dr. von Tresckow on "Sequential Triple-T" Trial in CLL

Julia von Tresckow, MD, specialist in oncology, University of Cologne, Department of Internal Medicine, and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, discusses the CLL2-BIG trial, which explored the combination of obinutuzumab (Gazyva) and ibrutinib (Imbruvica) for induction and maintenance treatment of physically fit and unfit patients with chronic lymphocytic leukemia (CLL). Patients with high tumor burden were given bendamustine as debulking.

Julia White, MD

Latest:

Dr. White on Research With Regional Nodal Irradiation in Node-Positive Breast Cancer

Julia R. White, MD, discusses research with regional nodal irradiation in node-positive breast cancer.

Julia Whiteker, MSN, RN

Latest:

Julia Whiteker Describes the ONS Breast Care SIG

Julia Whiteker Describes the ONS Breast Care SIG Online Community

Julian Adams, PhD

Latest:

Dr. Adams on Tackling Storage and Logistical Challenges in Cell Therapy

Julian Adams, PhD, discusses research efforts surrounding GDA-201, including details of the cryo buffer that the company developed in order to efficiently freeze and recover the GDA-201 cells.

Julian Kaye

Latest:

Dual Pathways Must Be Targeted in ER-Positive Breast Cancer

Treating estrogen receptorâ€“positive breast cancer without sparking resistance is a complex endeavor that should involve simultaneously targeting the hormone-signaling and PI3 kinase molecular pathways

Julie A. Kish, MD

Latest:

Prognostic Significance of Post-Treatment PET/CT Following Salvage Re-irradiation of Head and Neck Cancers

Researchers explored the prognostic significance of PET/CT following re-irradiation in patients with head and neck cancer.

Julie A. Sosa, MD, MS

Latest:

Dr. Sosa on Risk Factors for Thyroid Cancer

Julie Ann Sosa, MD, MA, FACS, FSSO, discusses risk factors for thyroid cancer.

Julie Cothren, DPh

Latest:

It's Time to Get Serious About New Rules for Handling Hazardous Drugs

Implementation of new standards for handling hazardous drugs in healthcare facilities is coming closer to reality now that the calendar has flipped to 2019.

Julie Djeu, PhD

Latest:

Modeling T-Cell Trafficking to Increase the Likelihood of Radiation-Induced Abscopal Effects

The combination of radiation and immunotherapy is currently enjoying unprecedented attention as a treatment strategy for patients with metastatic cancer.

Julie E. Bauman, MD

Latest:

Hedgehog Signal Inhibition Hope or Hype?

Once a human malignancy metastasizes, currently available cytotoxic chemotherapy is usually palliative. While conventional chemotherapy regimens are associated with objective tumor regression, this only occurs in a minority of patients.

Julie Graff, MD

Latest:

Dr. Graff Discusses the Treatment of Prostate Cancer

Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses the treatment of prostate cancer.

Julie Graff, MD, Oregon Health

Julie Gralow, MD

Latest:

Dr. Gralow on Future Challenges in Cancer Care in the Post–COVID-19 Era

Julie R. Gralow, MD, discusses future challenges in cancer care following the COVID-19 pandemic.

Julie Grisham

Latest:

Combining Chemo With mTOR Inhibitors Shows Promise in pNETS

Combining the chemotherapy streptozotocin with drugs that target the mTOR pathway may be an effective way to treat pancreatic neuroendocrine tumors.

Julie M. Vose, MD

Julie M. Vose, MD, MBA, professor and chief of the Division of Oncology and Hematology; and the George and Peggy Payne Distinguished Chair in Oncology at University of Nebraska Medical Center/Nebraska Medicine

Latest:

Dr Vose on Common Adverse Effects With Epcoritamab in Relapsed/Refractory LBCL

Julie M. Vose, MD, MBA, discusses the safety profile of epcoritamab in patients with relapsed/refractory LBCL who have achieved a 2-year complete response.

Julie N. Graff, MD

Latest:

Dr. Graff on Combination Regimens With Checkpoint Inhibitors in mCRPC

Julie N. Graff, MD, discusses potential combination regimens with checkpoint inhibitors in metastatic castration-resistant prostate cancer.

Julie R. Brahmer, MD

Julie Brahmer, MD, MSc, is the co-director of the Upper Aerodigestive Department at the Bloomberg-Kimmel Institute for Cancer Immunotherapy, the co-director of the Cancer Immunotherapy Program, the director of Thoracic Oncology, and the Marilyn Meyerhoff Professor in Thoracic Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Latest:

Lung Cancer Experts Highlight the Significance and Limitations of ADCs

Lung cancer experts discuss successes and hesitations regarding the evolving use of antibody-drug conjugates in non–small cell lung cancer.

Julie R. Gralow, MD

Latest:

Dr. Gralow on the Integration on Precision Medicine Into Oncology

Julie R. Gralow, MD, discusses the integration of precision medicine into oncology.